Standard Biotools Stock Performance

LAB Stock  USD 1.12  0.01  0.90%   
The entity has a beta of 1.41, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. At this point, Standard Biotools has a negative expected return of -0.0279%. Please make sure to validate Standard Biotools' jensen alpha, maximum drawdown, and the relationship between the coefficient of variation and sortino ratio , to decide if Standard Biotools performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Standard Biotools has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Standard Biotools is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
1
Acquisition by Casdin Partners Master Fund, L.p. of 450000 shares of Standard Biotools at 1.3028 subject to Rule 16b-3
11/20/2025
2
Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4325 subject to Rule 16b-3
11/24/2025
3
Acquisition by Casdin Partners Master Fund, L.p. of 125000 shares of Standard Biotools at 1.4201 subject to Rule 16b-3
12/02/2025
4
Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4468 subject to Rule 16b-3
12/04/2025
5
Single Cell Sample Preparation Market by Application, Country and Region, 2025-2035 - Demand Escalates for Single-Cell Research Tools Amid Rising Chronic Diseas...
12/10/2025
6
Standard BioTools Stock Price Down 3.9 percent - Time to Sell - MarketBeat
12/19/2025
7
Further weakness as Standard BioTools drops 15 percent this week, taking five-year losses to 80
12/31/2025
8
Contrasting Alternate Health Standard BioTools
01/07/2026
9
Standard BioTools Inc. Receives 1.35 Average PT from Analysts
01/12/2026
10
Standard BioTools Trading Up 5.6 percent Should You Buy
01/16/2026
11
Clover Health Investments vs. Standard BioTools Financial Analysis
01/26/2026
12
Standard BioTools Completes Sale of SomaLogic to Illumina
01/30/2026
13
STAND TOGETHER VENTURES LAB, CUBIT CAPITAL, 8VC, AND GSV INVEST IN TAP TO ACCELERATE AI-POWERED WORKFORCE DEVELOPMENT FOR ADVANCED MANUFACTURING
02/10/2026
14
Standard BioTools Inc. Stock Analysis Unpacking a .64 percent Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
02/13/2026
Begin Period Cash Flow52.5 M
Total Cashflows From Investing Activities363.2 M

Standard Biotools Relative Risk vs. Return Landscape

If you would invest  121.00  in Standard Biotools on November 17, 2025 and sell it today you would lose (9.00) from holding Standard Biotools or give up 7.44% of portfolio value over 90 days. Standard Biotools is generating negative expected returns assuming volatility of 4.5156% on return distribution over 90 days investment horizon. In other words, 40% of stocks are less volatile than Standard, and above 99% of all equities are expected to generate higher returns over the next 90 days.
  Expected Return   
       Risk  
Considering the 90-day investment horizon Standard Biotools is expected to under-perform the market. In addition to that, the company is 5.91 times more volatile than its market benchmark. It trades about -0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of volatility.

Standard Biotools Target Price Odds to finish over Current Price

The tendency of Standard Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 1.12 90 days 1.12 
roughly 97.0
Based on a normal probability distribution, the odds of Standard Biotools to move above the current price in 90 days from now is roughly 97.0 (This Standard Biotools probability density function shows the probability of Standard Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.41 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Standard Biotools will likely underperform. Additionally Standard Biotools has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Standard Biotools Price Density   
       Price  

Predictive Modules for Standard Biotools

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Standard Biotools. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.061.125.67
Details
Intrinsic
Valuation
LowRealHigh
0.071.305.85
Details
3 Analysts
Consensus
LowTargetHigh
1.411.551.72
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.01-0.01-0.01
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Standard Biotools. Your research has to be compared to or analyzed against Standard Biotools' peers to derive any actionable benefits. When done correctly, Standard Biotools' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Standard Biotools.

Standard Biotools Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Standard Biotools is not an exception. The market had few large corrections towards the Standard Biotools' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Standard Biotools, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Standard Biotools within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.07
β
Beta against Dow Jones1.41
σ
Overall volatility
0.15
Ir
Information ratio -0.0098

Standard Biotools Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Standard Biotools for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Standard Biotools can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Standard Biotools generated a negative expected return over the last 90 days
Standard Biotools may become a speculative penny stock
Standard Biotools has high historical volatility and very poor performance
The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 81.9 M.
Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Standard Biotools has a poor financial position based on the latest SEC disclosures
Over 78.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Standard BioTools Inc. Stock Analysis Unpacking a .64 percent Potential Upside in the Healthcare Sector - DirectorsTalk Interviews

Standard Biotools Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Standard Stock often depends not only on the future outlook of the current and potential Standard Biotools' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Standard Biotools' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding352.7 M
Cash And Short Term Investments292.9 M

Standard Biotools Fundamentals Growth

Standard Stock prices reflect investors' perceptions of the future prospects and financial health of Standard Biotools, and Standard Biotools fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Standard Stock performance.

About Standard Biotools Performance

By analyzing Standard Biotools' fundamental ratios, stakeholders can gain valuable insights into Standard Biotools' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Standard Biotools has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Standard Biotools has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 189.63  196.27 
Return On Tangible Assets(0.26)(0.28)
Return On Capital Employed(0.29)(0.30)
Return On Assets(0.20)(0.21)
Return On Equity(0.34)(0.36)

Things to note about Standard Biotools performance evaluation

Checking the ongoing alerts about Standard Biotools for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Standard Biotools help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Standard Biotools generated a negative expected return over the last 90 days
Standard Biotools may become a speculative penny stock
Standard Biotools has high historical volatility and very poor performance
The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 81.9 M.
Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Standard Biotools has a poor financial position based on the latest SEC disclosures
Over 78.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Standard BioTools Inc. Stock Analysis Unpacking a .64 percent Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Evaluating Standard Biotools' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Standard Biotools' stock performance include:
  • Analyzing Standard Biotools' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Standard Biotools' stock is overvalued or undervalued compared to its peers.
  • Examining Standard Biotools' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Standard Biotools' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Standard Biotools' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Standard Biotools' stock. These opinions can provide insight into Standard Biotools' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Standard Biotools' stock performance is not an exact science, and many factors can impact Standard Biotools' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Standard Stock analysis

When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Valuation
Check real value of public entities based on technical and fundamental data
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Fundamental Analysis
View fundamental data based on most recent published financial statements